Oncology Solutions
At Muriphys, we are revolutionizing oncology research with innovative solutions designed to accelerate your journey from discovery to clinical trials. Our expertise lies in developing cutting-edge preclinical mouse models derived from patient-derived xenografts (PDX). These advanced models offer unparalleled precision in compound evaluation, enabling robust efficacy studies that significantly shorten the timeline for preclinical cancer drug development.
SPEAK TO A SCIENTIST
BOOK A MEETINGPDX models utilize live mice with xenograft tumors, accurately mimicking a diverse range of human cancer types, including bladder, lung, and skin cancers. This approach ensures quicker, more reliable insights into therapeutic potential, providing a strong foundation for your transition to clinical phases. With our solutions, you can make data-driven decisions with confidence, supported by high-quality, reproducible results.
Accelerating Drug Development with Comprehensive Services
We go beyond efficacy studies to offer a suite of services that address every critical aspect of drug development. From pharmacokinetics to safety testing, our comprehensive evaluation framework ensures your therapeutic compounds are thoroughly assessed.
We accommodate a variety of therapeutic modalities, including:
- Monoclonal Antibodies
- Bispecific Antibodies
- Antibody-Drug Conjugates (ADCs)
- Small Molecules
Our flexible administration routes, detailed in our Pharmacokinetics and Drug Metabolism section, allow us to tailor studies to meet the specific needs of your therapeutic program.
Reliable and Predictive Study Timelines
Our research is designed to deliver timely, actionable results. The following timeline demonstrates the progression of a typical study utilizing a PDX mouse models. By leveraging these advanced preclinical tools, we provide reliable predictions of therapeutic efficacy, ensuring seamless translation to clinical applications.
Efficient Monitoring and Data Collection
Equipped with state-of-the-art facilities, we ensure accurate assessment of xenograft tumor development. Our methodologies include advanced imaging and measurement techniques, such as the use of clippers for precise tumor growth evaluation.
For example, in a 33-week pilot study, a tumor model mouse treated with 2 mg/kg of a therapeutic agent demonstrated measurable tumor response. This study highlights our capacity to generate meaningful, high-quality preclinical data that directly informs your drug development strategy.
Partner with Us to Advance Your Oncology Research
At Muriphys, we are dedicated to advancing the frontiers of oncology research. The PDX model provide a robust platform for evaluating cancer therapies with precision, helping you assess efficacy, pharmacokinetics, and safety efficiently.
By choosing our comprehensive services, you gain a trusted partner committed to de-risking your projects and accelerating your path to clinical success. Contact us today to discover how we can empower your oncology research and help bring innovative therapies to patients faster.
